{"id":"W3179570450","doi":"10.1097/qad.0000000000003025","title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.","year":2022,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Rilpivirine; Tolerability; Regimen; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Adverse effect; Atlas (anatomy); Viral load; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006525152,0.0002423736,0.0005014463,0.0001838232,0.0003024942,0.00001035382,0.00006807833,0.00002352012,0.0001009709],"category_scores_gemma":[0.0001377163,0.0001715479,0.0001045635,0.0003685813,0.00003023425,0.00006149077,0.00006258735,0.0001068613,0.000008436925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002799391,"about_ca_system_score_gemma":0.0002279606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001226351,"about_ca_topic_score_gemma":0.00002485947,"domain_scores_codex":[0.998181,0.0001170192,0.0004554463,0.0004542793,0.0005047506,0.0002874562],"domain_scores_gemma":[0.9988858,0.0002479891,0.0002276928,0.0003927134,0.0001463116,0.00009946393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0459896,0.04288298,0.3565994,0.0001965,0.00377951,0.001558161,0.03123809,0.0004464867,0.01627319,0.00004348684,0.002738327,0.4982543],"study_design_scores_gemma":[0.4712417,0.3354978,0.0454623,0.0006289362,0.008297066,0.000500936,0.05911576,0.01061183,0.04274637,0.00008505258,0.02426952,0.00154268],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958717,0.0001153108,0.000262248,0.0006035206,0.00007578496,0.002233541,0.0001051369,0.00006179108,0.0006709491],"genre_scores_gemma":[0.9726376,0.00000581212,0.008507164,0.00003238477,0.00006264786,0.0005630478,0.0004187166,0.00004230113,0.01773031],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4967116,"threshold_uncertainty_score":0.699552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06818869719114717,"score_gpt":0.3697766567304088,"score_spread":0.3015879595392617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}